These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 29391042)

  • 61. Global Programme to eliminate lymphatic filariasis: progress report on mass drug administration, 2010.
    Wkly Epidemiol Rec; 2011 Aug; 86(35):377-88. PubMed ID: 21887884
    [No Abstract]   [Full Text] [Related]  

  • 62. Repurposing auranofin as a lead candidate for treatment of lymphatic filariasis and onchocerciasis.
    Bulman CA; Bidlow CM; Lustigman S; Cho-Ngwa F; Williams D; Rascón AA; Tricoche N; Samje M; Bell A; Suzuki B; Lim KC; Supakorndej N; Supakorndej P; Wolfe AR; Knudsen GM; Chen S; Wilson C; Ang KH; Arkin M; Gut J; Franklin C; Marcellino C; McKerrow JH; Debnath A; Sakanari JA
    PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003534. PubMed ID: 25700363
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Progress and impact of 13 years of the global programme to eliminate lymphatic filariasis on reducing the burden of filarial disease.
    Ramaiah KD; Ottesen EA
    PLoS Negl Trop Dis; 2014 Nov; 8(11):e3319. PubMed ID: 25412180
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Major progress toward eliminating lymphatic filariasis.
    Ottesen EA
    N Engl J Med; 2002 Dec; 347(23):1885-6. PubMed ID: 12466515
    [No Abstract]   [Full Text] [Related]  

  • 65. Preventive chemotherapy reverses covert, lymphatic-associated tissue change in young people with lymphatic filariasis in Myanmar.
    Douglass J; Dykes L; Kelly-Hope L; Gordon S; Leggat P; Aye NN; Win SS; Wai T; Win YY; Nwe TW; Graves P
    Trop Med Int Health; 2019 Apr; 24(4):463-476. PubMed ID: 30706585
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Assessment of treatment impact on lymphatic filariasis in 13 districts of Benin: progress toward elimination in nine districts despite persistence of transmission in some areas.
    Boko-Collins PM; Ogouyemi-Hounto A; Adjinacou-Badou EG; Gbaguidi-Saizonou L; Dossa NI; Dare A; Ibikounle M; Zoerhoff KL; Cohn DA; Batcho W
    Parasit Vectors; 2019 May; 12(1):276. PubMed ID: 31146779
    [TBL] [Abstract][Full Text] [Related]  

  • 67. What Is Needed to Eradicate Lymphatic Filariasis? A Model-Based Assessment on the Impact of Scaling Up Mass Drug Administration Programs.
    Kastner RJ; Stone CM; Steinmann P; Tanner M; Tediosi F
    PLoS Negl Trop Dis; 2015; 9(10):e0004147. PubMed ID: 26451729
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Global programme to eliminate lymphatic filariasis.
    Wkly Epidemiol Rec; 2009 Oct; 84(42):437-44. PubMed ID: 19860021
    [No Abstract]   [Full Text] [Related]  

  • 69. Lymphatic filariasis and onchocerciasis.
    Taylor MJ; Hoerauf A; Bockarie M
    Lancet; 2010 Oct; 376(9747):1175-85. PubMed ID: 20739055
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Frequency, severity, and costs of adverse reactions following mass treatment for lymphatic filariasis using diethylcarbamazine and albendazole in Leogane, Haiti, 2000.
    McLaughlin SI; Radday J; Michel MC; Addiss DG; Beach MJ; Lammie PJ; Lammie J; Rheingans R; Lafontant J
    Am J Trop Med Hyg; 2003 May; 68(5):568-73. PubMed ID: 12812348
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Transmission assessment surveys in the Global Programme to Eliminate Lymphatic Filariasis: WHO position statement.
    Wkly Epidemiol Rec; 2012 Nov; 87(48):478-82. PubMed ID: 23213667
    [No Abstract]   [Full Text] [Related]  

  • 72. Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study.
    Irvine MA; Stolk WA; Smith ME; Subramanian S; Singh BK; Weil GJ; Michael E; Hollingsworth TD
    Lancet Infect Dis; 2017 Apr; 17(4):451-458. PubMed ID: 28012943
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Lessons Learned From Developing an Eradication Investment Case for Lymphatic Filariasis.
    Kastner RJ; Stone CM; Steinmann P; Tanner M; Tediosi F
    Adv Parasitol; 2016; 94():393-417. PubMed ID: 27756458
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Current practices in the management of lymphatic filariasis.
    Bockarie MJ; Taylor MJ; Gyapong JO
    Expert Rev Anti Infect Ther; 2009 Jun; 7(5):595-605. PubMed ID: 19485799
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Filaria control and elimination: diagnostic, monitoring and surveillance needs.
    Molyneux DH
    Trans R Soc Trop Med Hyg; 2009 Apr; 103(4):338-41. PubMed ID: 19181357
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The role of albendazole in programmes to eliminate lymphatic filariasis.
    Ottesen EA; Ismail MM; Horton J
    Parasitol Today; 1999 Sep; 15(9):382-6. PubMed ID: 10461168
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prevalence of Lymphatic Filariasis and Treatment Effectiveness of Albendazole/ Ivermectin in Individuals with HIV Co-infection in Southwest-Tanzania.
    Kroidl I; Saathof E; Maganga L; Clowes P; Maboko L; Hoerauf A; Makunde WH; Haule A; Mviombo P; Pitter B; Mgeni N; Mabuye J; Kowuor D; Mwingira U; Malecela MN; Löscher T; Hoelscher M
    PLoS Negl Trop Dis; 2016 Apr; 10(4):e0004618. PubMed ID: 27070786
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Filariasis: new drugs and new opportunities for lymphatic filariasis and onchocerciasis.
    Hoerauf A
    Curr Opin Infect Dis; 2008 Dec; 21(6):673-81. PubMed ID: 18978537
    [TBL] [Abstract][Full Text] [Related]  

  • 79. New insights into the biology of filarial infections.
    Specht S; Wanji S
    J Helminthol; 2009 Jun; 83(2):199-202. PubMed ID: 19379544
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A statistical approach to monitor ongoing intervention for control of lymphatic filariasis.
    Lakshmi A
    J Commun Dis; 2000 Mar; 32(1):10-6. PubMed ID: 11129559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.